Risk Factors for Abacavir-induced Hypersensitivity Syndrome in the “Real World
 
Abacavir/ABC (Ziagen) is a generally well-tolerated NRTI. However, up to 5% of patients may develop hypersensitivity syndrome (HSS) within the first weeks of treatment.

The objectives of this study were to describe the side effects of ABC, to evaluate the incidence of the ABC-HSS, and to identify the risk factors of HSS after first exposure to ABC in a cohort of patients followed up in a university HIV clinic.

The charts of all HIV-infected patients who started ABC between February 1998 and May 2002 were reviewed.

HSS was defined as the onset, within 8 weeks of ABC initiation, of either a skin rash associated with at least one of the following symptoms (fever, gastrointestinal symptoms, respiratory symptoms, myalgia, malaise) or at least three of the above symptoms in the absence of rash.

A multivariate logistic regression analysis was performed to identify risk factors of HSS.

Results

Of the 191 patients studied (134 M, 57 F, mean age 39 years), 53 (27.8%) presented with manifestations that were regarded as potential side effects of ABC. Ten (5.2%) developed HSS, none of whom died.

Two factors were independently associated with an increased risk of HSS: history of allergy to nevirapine (Viramune) (p = 0.02), and being naive to ART (p = 0.04).

Conclusion

In conclusion, the authors note, “This study "in the real world" confirms that the incidence of ABC-induced HSS is of about 5%. It also confirms that HSS occurs more frequently in patients with a history of allergy to nevirapine (Viramune) and in ART-naive patients.”

12/06/04

| Link to Index to All HIV/AIDS Articles by Topic A to Z